Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
Recurrent Liver Carcinoma

About this trial
This is an interventional treatment trial for Recurrent Liver Carcinoma focused on measuring Irreversible Electroporation, NK Immunotherapy, Recurrent Liver Carcinoma
Eligibility Criteria
Inclusion Criteria:
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
- Body tumor 1-6, the maximum tumor length < 5 cm
- KPS ≥ 70, lifespan > 6 months
- Platelet count ≥ 80×109/L,white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion Criteria:
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Sites / Locations
- Fuda cancer institute of Fuda cancer hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Electroporation and natural killer
Electroporation
In this group, the patients will receive regular irreversible electroporation (IRE) treatment in combination with multiple natural killer (NK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
In this group, the patients will receive regular irreversible electroporation (IRE) treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).